secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0001193125-22-189000
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

TScan appoints Dr. Debora Barton as Chief Medical Officer effective July 5, 2022
--------------------------------------------------------------------------------

- Appointed Dr. Debora Barton as CMO, effective July 5, 2022.
- Barton previously CMO at Carisma Therapeutics and SVP at Iovance Biotherapeutics.
- Employment terms: $450k base salary, option for 150k shares under 2021 equity plan.
- Option vests 25% after 12 months, remainder in 36 monthly installments; eligible for 40% bonus target.
- No family relationships or material transactions with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312522189000/0001193125-22-189000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312522189000/d537481d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-189000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer